Successful treatment and prevention of murine Pneumocystis carinii pneumonitis with 4,4'-sulfonylbisformanilide.
Pneumocystis carinii pneumonitis was prevented in 0, 50, 100, and 100% of immunosuppressed rats given doses of 0.5, 5.0, 25.0, and 125.0 mg/kg (body weight) per day, respectively, of 4,4'-sulfonylbisformanilide (DFD). Therapeutic efficacy was demonstrated with DFD at 25.0 mg/kg per day, and when this dose was combined with trimethoprim, the combination was as effective as trimethoprim-sulfamethoxazole, which has been proven to be effective in the treatment of murine and human P. carinii pneumonitis.
D000818:Animals; D003622:Dapsone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003907:Dexamethasone / Q000494:pharmacology; D004338:Drug Combinations / Q000627:therapeutic use; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy* / Q000517:prevention & control; D051381:Rats; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D004338:Drug Combinations; C100107:diformyl dapsone; D003907:Dexamethasone; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003622:Dapsone; D014295:Trimethoprim; D013420:Sulfamethoxazole